Immunotherapy for Alzheimer’s disease: hoops and hurdles

Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies

(2013) Hanna Rosenmann   Current Alzheimer Research

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

MER5101, a Novel A 1-15:DT Conjugate Vaccine, Generates a Robust Anti-A  Antibody Response and Attenuates A  Pathology and Cognitive Deficits in APPswe/PS1 E9 Transgenic Mice

(2013) B. Liu et al.   JOURNAL OF NEUROSCIENCE

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

(2010) Oliver Wirths et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

(2009) Richard J. Perrin et al.   NATURE

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET